Introduction
The serotonin syndrome (SS) in man is an adverse, toxic drug reaction which is a result of excessive serotonergic activity and is potentially life threatening. It typically occurs following ingestion of two or more drugs that enhance serotonin (5-HT) levels, but it can also be induced by an overdose of single drug use. Animal models of the SS can be helpful in uncovering drugs and drug combinations suspected in inducing the SS in humans, in addition to uncovering underlying neurobiological fundamentals of the SS. Whereas several reviews to date have focused on the SS in man [e.g. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , only four reviews have focused on basic research and animal models of the SS [5, [20] [21] [22] .
The aim of the current review is to provide a comprehensive assessment of the existing versions of the animal model of an SS, including a historical perspective, the commonalities and differences between various animal models of the SS, and the discussion of the utility of these models. To that end, we provide a brief overview of the SS in humans, including the symptoms of the SS, drugs implicated in the SS, and the incidence of the SS. We then review animal models of the SS focused on rats and mice, highlighting behavioral and autonomic responses, in addition to a discussion of assessment and quantification procedures. Based on the frequency of the various behavioral and autonomic responses induced by widely used direct and indirect 5-HT agonists, we outline the common behavioral and autonomic effects. Additionally, we briefly consider the involvement of various 5-HT receptor subtypes in the responses. Finally, we discuss the importance of standardization of assessment of SS responses in experimental research, and suggest directions for future research involving animal models of the SS.
The SS in humans

Terminology
Although 5-HT was already identified in 1949 by Rapport, the understanding that low synaptic 5-HT concentrations are involved in the pathogenesis of mood disorders was first gained at the beginning of the 1960s [23] . The awareness of the link between 5-HT and psychiatric disorders and the introduction of 5-HTenhancing drugs in therapy increased the attention of general practitioners for side-effects of serotonergic drugs and entailed the first descriptions of the symptoms in the 1960s [24] [25] [26] . Throughout the years, several terms have been used to describe the SS. Already in use in basic research, the term SS was first applied to the clinical syndrome in 1982 [27] . The SS is also referred to as a "toxidrome" as the syndrome consists of a pattern of characteristic unwanted symptoms and is induced by an overdose of drugs acting as direct or indirect 5-HT agonists [13] . Other terms including 5-HT toxicity [for a review: [12, 28] ] and 5-HT toxicity syndrome [29] have also been used.
Symptoms and diagnostic criteria
The symptoms of the SS in humans are categorized as a triad of signs which include mental state alterations (e.g. agitation, confusion), neuromuscular excitation (e.g. myoclonus, tremor), and autonomic dysregulation (e.g. hyperthermia, tachycardia) [for a review: [1] ]. It is thought that many symptoms of the SS are centrally mediated [1] , although excess serotonergic activity in the peripheral nervous system may also contribute to the spectrum of symptoms (e.g. vomiting, diarrhea, etc.) [30] .
The first detailed diagnostic criteria for the SS were introduced in 1991. Based on an evaluation of published clinical cases, the Sternbach criteria identified ten symptoms as being characteristic of the SS: confusion, hypomania, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhea, and incoordination [4] . The SS was diagnosed based on the presence of three of these symptoms, and whether these symptoms appeared subsequent to ingestion of 5-HT-enhancing drugs [4] . In 2003, the Hunter 5-HT Toxicity Scale was proposed based on a retrospective analysis of more than 2000 patients by the Hunter Area Toxicology Service (HATS) and provided decision rules for the diagnosis of the SS [31] . Compared to the earlier Sternbach criteria, the Hunter criteria are more specific, are simpler to use, are less likely to produce false positives, and are [2, 5, 21, 29, 124, 139, 143, 144] Autonomic dysregulation Diaphoresis, hyperthermia (>38 • C), diarrhea, shivering [3, 4, 31, 201, 245] Dysregulation in body temperature (up or down), [5, 21, 29, 124, 126, 139, 143, 184] Mental status alterations Agitation, confusion, incoordination, hyperactivity, hypomania, anxiety [3, 4, 31, 201, 245] Hyperactivity, hyperreactivity [5, 21] Other symptoms Bowel sounds, nausea, flushing, disorientation, hallucinations, mydriasis, hypersalivation, tachycardia Piloerection, defecation, salivation, hyperhidrosis [21, 74] Adapted from Kalueff et al. [22] . Main decision rule symptoms according to the Hunter 5-HT toxicity criteria [31] are written in italics.
focused on neuromuscular excitation and autonomic dysregulation instead of alterations in mental state [31] (see also Table 1 ).
As there is a partial overlap with symptoms of the SS, differential diagnoses for the SS include neuroleptic malignant syndrome, malignant hyperthermia, and anticholinergic intoxication [1] , thus confounding diagnosis of the SS. The neuroleptic malignant syndrome is caused by dopamine antagonists and is characterized by a slow onset and bradykinesia/akinesia in contrast to the SS that sticks out by a fast onset and hyperkinesia. In addition to "lead pipe" muscular rigidity, hyperthermia, fluctuating consciousness, and autonomic instability argue for neuroleptic malignant syndrome [1] . Malignant hyperthermia appears after exposure to inhalant anesthetics or succinylcholine and stands out by the raise in body temperature up to 46 • C, mottled skin, and hyporeflexia [1] . Anticholinergic poisoning has in common with the SS mydriasis, agitated delirium, and autonomic responses, but can be distinguished from the SS by the absence of bowel sounds and normal muscular tone and reflexes [1] . In addition, the mental state alterations observed in cases of the SS also occur in other disorders (e.g. anticholinergic delirium), and can complicate diagnosis of the SS [19] . However, current diagnostic criteria for the SS including the Hunter 5-HT Toxicity Scale require a medication history of prior ingestion of serotonergic substances [31] .
Causative drugs
Commonly, the SS results from an excess of synaptic 5-HT following ingestion of drugs that enhance serotonergic transmission either by increasing 5-HT synthesis or release, or by inhibiting 5-HT uptake or degradation [2, 28] . Several classes of antidepressant drugs have been implicated in the SS, including 5-HT reuptake inhibitors (SRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [11, 32] . The risk of precipitating the SS is increased if serotonergic drugs with different mechanisms of action are ingested, even weeks apart [19] . However, in rare cases the SS also developed after single drug use of SRIs (e.g. citalopram, fluvoxamine, sertraline) or MAOIs (e.g. moclobemide) in an overdose [33] [34] [35] . Although selective SRIs (SSRIs) have been shown to induce fewer side-effects [36] , an analysis of 469 overdose admissions to a toxicology unit a non-life-threatening SS occurred in 14% of cases [32] . However, life-threatening toxicity has only been observed following the combination of an SSRI with other 5-HT-enhancing drugs [11] . TCAs act predominantly at the serotonergic as well as the adrenergic system, with compound-dependent effects involving other neurotransmitter systems (e.g. the cholinergic and the histaminergic system) [37] . The ability of TCAs and SRIs to elicit the SS correlates with the particular drug's affinity for the 5-HT transporter (5-HTT) [11] .
In addition to antidepressant compounds, other types of drugs have been implicated in the SS including mood stabilizers, opioid analgesics, illicit drugs, and possibly drugs used in the treatment of migraine [for a review: [1, 13, 38] ]. Recently, opioids such as tramadol and pethidine (meperidine), which in addition to effects on the opioid receptors have serotonergic actions [39, 40] , have also been implicated in the SS [for a review: [11] ]. Several illicit drugs which block reuptake and/or increase release of 5-HT have been implicated in the SS, for example 3,4-methylenedioxy-N-methamphetamine (MDMA; "ecstasy") and cocaine [41] [42] [43] [44] . Factors that have been shown to increase the risk of the SS associated with illicit drug ingestion, include high doses, repeated use, and ingestion in combination with another illicit compound or with a MAOI [14, 45] .
Additional drugs, which may be causative of the SS, include the amino acid precursors of 5-HT, tryptophan and 5-hydroxyl-tryptophan (5-HTP) [2, 26, 46] . Increased availability of 5-HT precursors augments the amount of available 5-HT, which might lead to the development of the SS [2] . In January 2013 the FDA MedWatch Safety Alert still reminds that precautions have to be taken if SSRIs are combined with 5-HT precursors like tryptophan. However, studies investigating the combination of tryptophan with fluoxetine or MAOIs indicate that side-effects are modest if tryptophan dosage is not exceeded [47] [48] [49] . Triptans used to treat migraine are agonists at 5-HT 1B/1D receptors [50] , and their potential to trigger the SS is currently under discussion [51, 52] . In fact, based on 29 reported cases, a recent FDA MedWatch Safety Alert (August 2010) warned against concomitant use of triptans with SSRIs or 5-HT/norepinephrine reuptake inhibitors (SNRIs), as these drug combinations were thought to cause an SS [53] . In addition, there is evidence of the development of the SS following concomitant ingestion of an SSRI or an SNRI and the antibiotic linezolid or methylene blue, which is used as a standard dye for intraoperative identification of the parathyroid glands [2, [54] [55] [56] . The latter two compounds have reversible MAOI properties, linezolid inhibits the enzyme non-selectively, whereas methylene blue preferentially inhibits MAOA [55, 57, 58] . Herbal remedies such as St. John's Wort (Hypericum) may also contribute to the SS [59] .
So far, it has not been clarified whether the SS is a result of overall 5-HT receptor activation or whether it can be attributed to stimulation of specific 5-HT receptor subtypes. The evidence supporting the latter assumption is little and focuses on the involvement of 5-HT 1A and 5-HT 2A receptors. Some case reports suggest that addition of anxiolytic 5-HT 1A receptor agonists, like buspirone or tandospirone, to antidepressant treatment may increase the risk of the SS [60] [61] [62] [63] . Two recent studies report that the new designer drug 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), which is a high potent 5-HT 2A receptor agonist, provoked severe clinical intoxication including tachycardia, hypertension, agitation, aggression, visual and auditory hallucinations, hyperpyrexia and clonus in several cases [64, 65] . Most of these symptoms are also observed in patients with SS. In vitro experiments with human skeletal muscle specimens indicate that 5-HT 2A receptor activation is involved in hyperthermia, which is a main symptom of SS in humans [see 5] . Animal experiments and studies in humans allude that the hyperthermic effect induced by 5-HT-enhancing drugs might be ameliorated or prevented by 5-HT 2A antagonists [see 13, 28] .
Incidence
It has been suggested that the SS has become an increasingly common clinical problem, mirroring the rising use of drugs that enhance serotonergic transmission [32, 66, 67] . Due to the heterogeneity of the SS and still a broad lack of awareness of the SS by general practitioners, the SS is thought to be underreported [1, 68] . As comprehensive epidemiologic studies are not available, evidence regarding the incidence of the SS is mostly based on individual case reports and post-marketing drug outcome studies. For example, in a routine post-marketing surveillance study of nefazodone (a 5-HT/norepinephrine/dopamine reuptake inhibitor) [69] , the incidence rate (number of cases per 1000 patient-months of treatment) for the SS (two or more symptoms according to Sternbach's diagnostic criteria) was assessed. The incidence rate of nefazodone-associated SS was 0.4, similar to rates for the SSRI paroxetine and the SNRI venlafaxine [68] . Further, a study in Australian Veterans showed that tramadol and other 5-HTenhancing drugs are frequently co-prescribed [70] , and were the most frequent fatal drug combinations in a study of drug-associated fatalities in Victoria, Australia from 2002 to 2008 [71] .
Measuring the SS in animals -a general survey
Terminology and history
In animals, administration of certain direct and indirect 5-HT agonists induces a set of behavioral and autonomic responses (described below and see Table 1 ). Reported since the 1950s [72, 73] , these responses in laboratory animals follow increased serotonergic tone or direct agonism at specific serotonin receptors, and some of these responses resemble the SS in man [21, 22] . To our knowledge, the term "serotonin syndrome" in animal models was first explicitly used in 1979 by Hwang and Van Woert [74] , although previous publications described a pattern of behavioral effects following administration of direct and indirect 5-HT agonists [e.g. 21, 75] .
Since the discovery of 5-HT and subsequent investigations describing 5-HT biosynthesis, 5-HT metabolism, and the various physiological functions of 5-HT [76, 77] [for a review: [78] ], numerous pharmacological compounds that manipulate the 5-HT system have been developed. 5-HT in contrast to its precursor 5-HTP does not cross the blood-brain barrier [79] , hence its centrally mediated side-effects cannot be investigated following systemic administration. However, central 5-HT concentration can be markedly increased by peripheral administration of 5-HTP in high doses resulting in various behavioral and autonomic responses. These responses include tremor, ataxia, loss of plantar reflex, gastrointestinal effects, pupil dilatation, piloerection, and increased motor activity in various species [80] . Interestingly, these early studies revealed that the characteristic 5-HTP-induced responses were produced by lower doses of 5-HTP when the MAOI iproniazide was co-administered [72, 81, 82] . As such, Shore and Brodie [82] concluded that these responses were caused by an "excess of free 5-HT".
Behavioral responses and history
Jacobs [83] was the first researcher to score and report "the serotonin-mediated behavioral syndrome" in rats, and similar responses were first reported in mice in 1979 [74] . In the original rat studies, behaviors were rated in degrees of severity on a scale ranging from not-present, to moderate, to marked symptoms [84] . The six characteristic responses observed were forepaw treading, resting tremor, rigidity, Straub tail, hind limb abduction, and head weaving [21, 85] , and it was subsequently proposed that the presence of at least any four of six of these responses demonstrated increased activity of the serotonergic system and hence resembles a syndrome [21] . These assessment and rating methods introduced by Jacobs were later refined, and time-courses and dose-effect relationships for these responses were included [86, 87] . Backward walking/movement and low body posture (also referred to as flat body posture) were added in the 1980s as additional SS behavioral responses [88] [89] [90] . Kennett et al. [90] assessed intermittent, continuous, and quantifiable behavioral responses. This assessment method has been widely accepted and several variations of this scoring system have been developed. The set of responses, which were firstly studied by Kennett et al. [90] will be designated in the following as "traditional responses/traditional SS behaviors" (see Section 4.4.1). Data are often given as a cumulative score or as a mean score [e.g. [91] [92] [93] . The cumulative score of a response sums up the scores collected for each animal over a specific period, resulting in one value per animal and a mean with standard deviation can be calculated for each group. The mean score is the mean of all scores of a group at specific time points. This bears the advantage to provide information about the time course of a response. When authors declare the occurrence of an SS independent of the number or the spectrum of observed responses it is referred in the following to an "overall SS".
Although not always directly considered part of the SS in animals, additional behavioral responses that result from increased serotonergic tone or by direct agonism at 5-HT 2A receptors are head twitches in mice [e.g. [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] and wet dog shakes in rats [e.g. [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] . In the literature, most authors consider the two responses as entities separate from the SS, whereas other researchers do regard these responses as part of the SS [e.g. 5, 84, 89, 95, 96] .
Autonomic responses
Autonomic responses induced by serotonergic hyperactivity in rats include changes in body temperature, exophthalmos (bulging eyes), lower lip retraction, penile erection, piloerection, and salivation, which can be observed by close examination for wet fur or by placing an absorbent tissue in the mouth [120] [121] [122] [123] [124] . In mice, autonomic responses other than body temperature have rarely been reported [74, 125] . It should be noted that there are species differences in thermoregulation. 5-HT-enhancing drugs have a hyperthermic effect in rats [122, 126, 127] , whereas the same drugs induce a hypothermic response in mice [128, 129] . Further, 5-HT 2A receptor agonists elicit hyperthermia in rats [130, 131] but hypothermia in mice [132, 133] . 5-HT 1A agonists induce hypothermia in both species, but probably by acting at two different (preor postsynaptic) 5-HT 1A receptor sites [134, 135] .
Quantification and assessment procedures
As described, serotonergic hyperactivity induced by direct and indirect 5-HT agonists produces several behavioral and autonomic responses in rats and mice, and the responses that have been assessed and reported vary between laboratories. Quantification of SS responses has been achieved in various ways. The quantification procedures can be categorized as ratio scale (including interval scale) and nominal scale approaches [29] , and can be used for individual responses and for reporting an "overall SS".
Ratio scale approaches can be used when a response is countable or measureable. For example, discrete events such as wet dog shakes in rats can be counted over the observation period or in time blocks [114, [136] [137] [138] . Further responses measurable by ratio scale approaches include motor activity and locomotion, whereas body temperature is measured by interval scales [e.g. 86, 110, 139] . Nominal scale approaches include categorical assessments (for a single response, or "overall SS" is present versus absent) and ordinal assessments (assessments made on scales based on frequency or intensity). Using categorical procedures, SS responses are assessed at several time points within an observation period, and the occurrence of responses at the various time points can subsequently be summed up [140] [141] [142] . Another categorical approach is to report the presence or absence of an "overall SS" depending upon whether or not a predetermined number of specific responses is present [21] . Ordinal scales can be used to assess intermittent and continuous behavioral responses [90, 143, 144] . Intermittent responses such as head weaving, forepaw treading, and backward movement can be recorded as absent, present once, present several times, or present. Continuous responses such as tremor, low body posture, Straub tail, and hind limb abduction can be recorded on scales based on the intensity of the behavior. The scores for each response using intermittent and continuous scales can be summed up individually, and a cumulative score for several responses can be calculated for an "overall SS" score [29, 124, 125, 143] .
A systematic analysis of SS responses in animals
Aim
The aim of the current analysis is to provide a comprehensive assessment of the variety of animal models of the SS including the commonalities and differences between the different versions, in addition to an examination of the behavioral and autonomic responses induced by various serotonergic drugs. Based on the frequency of the reported responses, we will extract those core responses that reliably characterize the SS in rats and mice independent from the used serotonergic drug or drug combination. These core symptoms will serve to increase the predictive validity of the animal model and provide a basis on which the assessment of responses can be standardized. To that end, we systematically reviewed the literature on animal models of the SS, and extracted data on the effects of various direct and indirect 5-HT agonists, administered alone or in combination.
Inclusion criteria
The search was restricted to peer-reviewed journals. Publications were located by searching Pubmed starting with the discovery of 5-HT [76] . This initial search resulted in hundreds of articles, which were subsequently manually reviewed, and their inclusion was considered on the basis of their title and information included in the abstract. Specifically, if the publication included findings of acute pharmacological effects of serotonergic drug treatment in laboratory animals, the original article was acquired (also see exclusion criteria in Section 4.2). Further publications were identified within the reference section of the acquired articles, and additional publications of interest which met the inclusion criteria were included.
Data regarding SS responses induced by various serotonergic drugs were extracted from each publication, and the data were tabulated. If a publication reported results from multiple experiments, the publication was numbered and counted as a single publication (i.e. counting was based at the level of the publication, not at the level of the experiment). For example, Dickenson and Curzon [92] measured hind limb abduction following administration of several different serotonergic drugs administered alone or in combination. For the purposes of the current review, this counted as a single publication (e.g. when the number of publications reporting hind limb abduction are reported), and the breakdown of the results for each individual drug and/or drug combination are included in Tables 2 and 3 . In the following analysis only responses which are reported more than once were considered.
Exclusion criteria
Publications were excluded if they were not in English or if they did not contain original research (i.e. reviews). Papers were also excluded if they reported: effects in humans, in non-mammalian animals, or in non-laboratory animals; effects in transgenic animals with alterations in neurotransmission systems other than the serotonergic system; effects not caused by acute serotonergic drug treatment (e.g. chronic treatment, non-serotonergic drugs); syndromes not associated with serotonergic drugs; effects of serotonergic compounds in specific cells or peripheral areas (e.g. platelets or gut); in vitro effects; effects restricted to 5-HT antagonists; or results of drug screenings.
Additional considerations 4.4.1. Terminology and description of SS responses
There is considerable heterogeneity in animal models of the SS reported in the literature. The use of different assessment methods, different sets of responses, and different scales when assessing the effects of increased serotonergic tone limit quantitative comparisons of results across laboratories. As such, for the current analysis, we extracted only qualitative information from the literature, i.e. the presence of various responses elicited by treatment with serotonergic drugs was investigated, whereas data regarding time-effect or dose-response relationships were not included.
It should be noted that there is a large literature describing head twitches in mice. As the focus of the current review is the SS, studies reporting head twitches in mice were only included if they were part of an assessment of the SS (although some additional studies are included in Section 6). Regarding rats, the terms used for movements of the head and body have been used inconsistently, and there are disparate definitions of these terms in the literature. For example, in rats there is overlap in the use of the terms "wet dog shakes," "head shakes," "head twitches," "body twitches," "tremor," and "tremor restricted to head" [85, 89, 92, 99, 108, 109, 114, 119, 120, 136, [145] [146] [147] [148] . These issues complicate comparison of these responses across studies. As such, behaviors reported here are described and defined based on the term used within each publication and were only included if they were part of a study of the SS. For the current analysis, the seven responses highlighted by Kennett et al. [90] , i.e. head weaving, forepaw treading, backward movement, hind limb abduction, Straub tail, tremor, and low body posture, which are well-known to be associated with the overactivation of the serotonergic system, will be referred to as "traditional SS behaviors" [21, 90, 128, 138, 143, 144, 149, 150] . It has to be noted, that one of the aims of this review is whether these "traditional SS behaviors" belong to the core responses of the SS in rodents.
Species
Initially, 120 publications were obtained by the above described search and inclusion criteria. Eleven of these publications investigated the manifestations of increased serotonergic tone in species other than mice and rats, i.e. dogs [72, 80, 151] , rabbits [73, 152] , cats [80] , guinea-pigs [153, 154] , mongolian gerbils [155] , tree shrews [156] , monkeys [157] [158] [159] , and pigeons [73] . As data on species other than mice and rats are infrequent, conclusions drawn from a comparative analysis of these studies are difficult to interpret. As such, the current analysis was restricted to rats and mice.
Genetic animal models of the SS
Several studies of behavioral and autonomic responses have focused on mice with genetic alterations to mechanisms involved in serotonergic transmission [125, 128, 139, 143, 149, 150] . Genetic animal models of the SS were the subject of a recent review [22] and are beyond the scope of the current paper. Therefore, results describing SS responses in transgenic animals are excluded from the current review, although findings regarding the wildtype animals in these genetic studies are included.
Results of the analysis
Based on the criteria described above, 109 publications were identified for inclusion in the current analysis and review. These publications comprise investigations of behavioral and/or autonomic manifestations of the SS in rats (85) , in mice (20) , or in both species (4). As such, 89 studies using rats and 24 studies using mice were incorporated into the analyses reported below.
Strain and sex differences
Most of the publications included in the current review contained information regarding the strain and the sex of rats and mice. As differences in responses based on the strain and/or the sex of rats and mice have not been consistently investigated or reported, it was not possible to draw conclusions regarding strain or sex differences in SS responses.
In rats, only a few strains have been investigated. The most frequently investigated strain of rats was Sprague-Dawley (53 out of 89 studies), followed by Wistar (28/89), albino (Tif: RAIf) (3/89), hooded (2/89), and Long Evans (1/89). Three publications did not report the strain of the rats. A total of 11 different mouse strains have been assessed, with no strain investigated preferentially. Manifestations of the SS in mice have been assessed in the following strains: C57Bl/6, ddY, and NMRI (each: 4 out of 24 studies), ICR, DBA, Swiss Webster, and CD1 (each: 2/24), and four additional strains (C3H, albino Tuck, MFI, 129/SvPAS) were investigated only once.
To the best of our knowledge, one study specifically examined strain differences in SS responses. Yamada et al. [160] investigated the effect of tryptamine on head weaving, hind limb abduction, and head twitches in five mouse strains (C57Bl/6, ICR, DBA, ddY, and C3H) and found out that the intensity of head weaving and hind limb abduction, but not of head twitches, is correlated to the tryptamine concentration in the brain, which differed between the strains. Moreover, 5-HT 2 receptor binding studies suggested that strain differences in the occurrence of head twitches is linked to differences in 5-HT 2 receptor functionality [160] .
In the majority of the studies, the SS was induced in male rats (79/89) and mice (18/24) . Investigations in female rodents were performed twice in both species [112, 119, 135, 143] . Six studies (five in rats and one in mice) reported the responses in both sexes. Three studies in rats and one study in mice did not report the sex of the animals investigated. Two comparative investigations in rats noted quantitative and temporal differences in drug responses in male versus female rats [92, 142] . In the additional three rat studies investigating both sexes, the rats were not separated by sex for analysis [87, 114, 161] . In a study investigating sex differences in wildtype and transgenic mice, no differences in overall 5-HTP-induced SS behaviors were found between male and female mice [128] .
Taken together, there is insufficient data to draw conclusions of the impact of differences in strain or sex on SS responses in laboratory rodents. However, possible effects of strain and sex should be taken into account in future investigations.
Studies in rats
89 publications reported SS responses in rats. Table 2 
Behavioral responses and involved 5-HT receptors
Regarding "traditional SS behaviors" in rats, forepaw treading (56 studies out of 89), head weaving (37/89), hind limb abduction (41/89), tremor (22/89), Straub tail (23/89), and low body posture (22/89) were observed most frequently, followed by the rarely assessed backward walking (3/89) (Table 2a) . Additional behavioral responses were also reported, including changes in locomotor activity (14/89), hyperactivity (any increase of motor activity, 21/89), wet dog shakes (12/89), rigidity (8/89), head twitches (7/89), head shakes (7/89), hyperreactivity (i.e. increased startle response to an acoustic or tactile stimulus, 5/89), body twitches (4/89), myoclonus (5/89), changes in rearing (4/89), and chewing (2/89; see Table 2b ). The three most frequently observed responses -forepaw treading, head weaving and hind limb abduction -often occurred together (25/89) . Approximately half of these studies additionally described the occurrence of tremor (14/25) or Straub tail (17/25) . Further, low body posture (10/25), rigidity (5/25), and hyperreactivity (4/25) were also reported together with the three most frequently observed behaviors.
It is widely accepted that 5-HT 1A receptors mediate most SS behavioral responses in rats [e.g. 5, 89, 124, 147, [162] [163] [164] [165] [166] [167] . For example, the full 5-HT 1A agonist 8-OH-DPAT has been shown to induce low body posture, forepaw treading, and hyperlocomotion, and these responses are dose-dependently antagonized by 5-HT 1A antagonists such as WAY 100635 [162, 168, 169] . Although 8-OH-DPAT has also affinity at 5-HT 7 receptors [170] , to date there is no evidence suggesting a role for 5-HT 7 receptors in SS behaviors in rats [e.g. 163, 167, 171] . The partial 5-HT 1A agonists, buspirone and ipsapirone, have been shown to induce a narrower spectrum of responses compared to 8-OH-DPAT. Both partial agonists induce low body posture, and buspirone has also been shown to induce hind limb abduction and Straub tail [167] .
Other behavioral responses in rats, such as head shakes, head twitches, and wet dog shakes, are mediated by 5-HT 2A receptors [5, 96, 119, 172] . For example, wet dog shakes and head shakes induced by 5-HTP or the combination of the MAOA/B-I phenelzine and the SSRI paroxetine were dose-dependently antagonized by 5-HT 2 antagonists [115, 119] . Further, head twitches induced by central administration of the 5-HT 2A/2C agonist DOI were antagonized by a selective 5-HT 2A antagonist, but not by a 5-HT 2C/2B antagonist [107] .
There is also evidence suggesting functional interactions between 5-HT 1A and 5-HT 2A receptors in rats. For example, the non-selective ˇ1/ˇ2 receptor antagonist propranolol, which has 5-HT 1A antagonist properties, has been shown to attenuate both 5-HT 1A and 5-HT 2 receptor-mediated responses [162] . Further, 8-OH-DPAT-induced responses are potentiated by administration of the 5-HT 2A/2C agonist DOI or the 5-HT 2A/2C/3 agonist quipazine [163, 173] . Studies have also reported that quipazine induces forepaw treading, head weaving, and hind limb abduction, similar to responses observed following administration of 8-OH-DPAT in rats [174] [175] [176] [177] .
Several studies (5/89) investigated central mediation of SS behaviors by microinjections of serotonergic compounds into the brain. Such serotonergic compounds included: 5-HT; 5-HT in combination with the MAOA/B-I tranylcypromine; and agonists at 5-HT 1A (8-OH-DPAT) or 5-HT 2A (DOI) receptors [107, 117, 136, 178, 179] . Central administration of 5-HT induced head shaking, forepaw treading, head weaving, hind limb abduction, tremor, hyperreactivity, and wet dog shakes [178] . Intracerebral microinjection of 8-OH-DPAT induced forepaw treading, hind limb abduction, and low body posture [179] , whereas DOI induced wet dog shakes [117] and head twitches [107] . These studies provide evidence of central induction of these behavioral responses, mediated by 5-HT 1A and 5-HT 2A receptors respectively.
Autonomic responses and involved 5-HT receptors
Autonomic SS responses in rats following administration of serotonergic drugs administered alone or in combination are reported in Table 2c . The most frequently reported response was a change in body temperature (26/89). As mentioned, other autonomic responses like lower lip retraction (3/89), penile erection (2/89), piloerection (3/89), and salivation (4/89) were rarely assessed.
Increases in body temperature were frequently reported following drug combinations (15/26), in particular following administration of a drug in combination with an inhibitor of MAOA-I (clorgyline). Of note, it has been highlighted that ingestion of an MAOI in combination with an SSRI elicits severe toxic serotonergic events in humans, including hyperthermia [11] . Interestingly, the administration of the MAOB-I pargyline or the non-selective MAOA/B-I tranylcypromine (5/26) administered alone induced a decrease in body temperature in rats.
Antagonism studies confirm the involvement of 5-HT 1A and 5-HT 2A receptors in thermoregulation in rats. It was shown that a decrease in body temperature in rats is mediated by activation of 5-HT 1A receptors [162, 180, 181] , whereas activation of 5-HT 2A receptors induces hyperthermia [124, 130, 131] . The opposing and possibly competing effects of 5-HT 1A and 5-HT 2A receptor activation are thought to have an impact on the temperature changes observed in studies using 5-HT-enhancing drugs. For example, following administration of a combination of 5-HTP and the MAOA-I clorgyline, body temperature changed in a dose-dependent manner. Specifically, hypothermia was observed following administration of lower doses, whereas hyperthermia was observed following higher doses [29, 124] . It should be noted that 5-HT has different affinities at 5-HT 1A and 5-HT 2A receptors; the affinity of 5-HT at 5-HT 1A receptors is ∼400-1000 times higher than at 5-HT 2A receptors [96, 182, 183] . As such, it is suggested that the effects of increased 5-HT at 5-HT 1A receptors occur at low 5-HT concentrations [5, 124] , whereas with increasing 5-HT availability, 5-HT 2A receptor activation dominates and body temperature is increased [5, 124] .
Another autonomic response shown to be induced by serotonergic drugs in rats is diarrhea, likely associated with reported increases in 5-HT in intestinal tissue [184] . Indeed, gastrointestinal symptoms of the SS in humans (e.g. vomiting and diarrhea) have been reported, suggesting the involvement of the enteric nervous system [4, 31] .
Studies in mice
Twenty-four publications reporting SS responses in mice were analyzed. Table 3 provides a comprehensive list of these responses in mice induced by various direct or indirect 5-HT agonists administered alone or in combination, by systemic or central route of administration.
Drugs
Serotonergic drugs, that induced SS responses in mice, include 5-HT-enhancing drugs and direct agonists at 5-HT receptors either administered alone or in combination (Table 3) . 5-HTenhancing drugs consist of: 5-HT precursors (5-HTP (administered alone or with a decarboxylase inhibitor), tryptamine, tryptophan); 5-HT releasers (fenfluramine, pCA, para-chlorophenyletylamine (pCPEA)); inhibitors of MAO (MAOA-I (clorgyline), MAOB-I (pargyline), MAOA/B-I (tranylcypromine); SSRIs (escitalopram, fluoxetine, paroxetine, sertraline, zimelidine); and a TCA (clomipramine). Direct agonists include: full 5-HT 1A receptor agonists (8-OH-DPAT, RU24969); and a partial 5-HT 1A receptor agonist (buspirone).
Behavioral responses and involved 5-HT receptors
In mice, the "traditional SS behaviors" reported most frequently were hind limb abduction (10/24) and head weaving (9/24), followed by Straub tail (7/24), tremor (6/24), low body posture (5/24), backward movement (5/24), and forepaw treading (4/24) ( Table 3) . Head weaving and hind limb abduction were frequently observed together (8/24) , and this combination of behaviors was observed together with forepaw treading (3/8), tremor (3/8), and Straub tail (3/8). Additional behavioral responses that were reported include hyperactivity (5/24), changes in locomotion (3/24), and rearing (2/24) ( Table 3) .
In mice, postsynaptic 5-HT 1A receptors mediate most SS behaviors [143, 167, 185] . The full 5-HT 1A agonist 8-OH-DPAT has been shown to elicit the "traditional SS behaviors" in addition to other behavioral responses listed in Table 3 , with the exception of hyperactivity [139, 140, 143, 167, 185] . In a recent study, pretreatment with the 5-HT 2B receptor antagonist RS127445 exacerbated fluoxetine-induced SS responses, including backward walking, hind limb abduction, low body posture, Straub tail, and tremor, suggesting a possible role of this receptor in SS responses in mice [125] . As noted, head twitches are mediated by 5-HT 2A receptors [133, [186] [187] [188] [189] . In addition to being induced by 5-HT 2A agonists such as TCB-2 (4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide) and DOI [133] , head twitches are also induced by 5-HT-enhancing drugs such as 5-HTP and the MAOB-I pargyline [188, 190, 191] . The effects are blocked by 5-HT 2A antagonists [133] .
As reported in rats, studies have also demonstrated a functional relationship between 5-HT 1A and 5-HT 2A receptors in mice [95, 133, 186, 192] . For example, 8-OH-DPAT has been shown to attenuate head twitches induced by 5-HTP or DOI [100, 133, 162] , while the partial 5-HT 1A agonist buspirone has been shown to increase head twitches induced by 5-HTP plus pargyline [190] .
In mice, central mediation of SS behaviors has been investigated by microinjection of drugs directly into the brain, or by co-administration of 5-HT precursors and peripheral decarboxylase inhibitors to increase 5-HT levels selectively in the central nervous system (Table 3) [191, 193] . Following microinjection of 5-HT into the brain [88] , backward walking was reported in one study [88] . After concomitant administration of 5-HTP and decarboxylase inhibitors to centrally increase 5-HT levels, hyperactivity was reported [194, 195] . Microinjection of drugs into the brain, and the combination of 5-HTP with a peripheral decarboxylase inhibitor, were shown to induce head twitches in mice [101, 105, 106, 162, 188] . Results of these studies show that central mechanisms are involved in the induction of these behavioral responses in mice.
Autonomic responses and involved 5-HT receptors
Body temperature was the most frequently assessed autonomic response in mice (6/24) (Table 3 ). In addition, piloerection was reported twice [74, 125] and salivation was reported once [74] . 5-HT precursors, 8-OH-DPAT, fenfluramine, and the combination of 5-HTP with an inhibitor of MAOA/B or MAOA have all been shown to decrease temperature in mice (Table 3) . In contrast to rats, 5-HT 2A receptor activation induces hypothermia in mice. For example, administration of DOI or TCB-2 induces hypothermia in mice [133] , and antagonism studies suggest that this is likely due to activity at 5-HT 2A receptors [133, 196] . Another receptor that has been implicated in thermoregulation in mice is the 5-HT 7 receptor [197] . For example, the selective 5-HT 7 antagonists SB 269970 and SB 258719 have been shown to block the hypothermic response to 5-carboxamidotryptamine (5-CT) [197] . However, SB 269970 had no effect on 5-HTP induced hypothermia, and did not affect SS behaviors in mice [143] . The only drug that increased temperature in mice was the 5-HT releaser pCA [198] . Studies suggest that the hyperthermic effect of pCA is due to activity at the D 1 receptor, as D 1 receptor antagonists blocked pCA-induced hyperthermia [198] .
Intracerebral injection of 5-HT, tryptamine, or 8-OH-DPAT induced hypothermia in mice [129, 134, 199] . Peripheral administration of 5-HT, which does not cross the blood brain barrier, dose-dependently decreased body temperature [200] in mice, an effect blocked by 5-HT 2 antagonists [200] . Thus, the activation of at least central 5-HT 1A receptors and peripheral 5-HT 2A receptors regulates body temperature in mice.
Discussion
In the current review, we analyzed data from 109 publications that reported behavioral and autonomic responses in rats and mice induced by acute administration of 5-HT-enhancing drugs and agonists at 5-HT receptors. Based on our analysis, we reported the specific responses induced by different serotonergic drugs, in addition to the frequency of these responses. We briefly discussed the receptor mediation of these responses. Here, we will discuss the utility of a standardized animal model of the SS in translational research and suggest directions for future studies.
A standardized animal model of the SS
In clinics the symptoms that are essential for the diagnosis of the SS are well defined [e.g. 4,31] (see also Table 1 ). In preclinical research every effect in rats and mice that was induced by 5-HT-enhancing drugs or direct 5-HT agonists was regarded as a component of the SS. Over the last decades a wide variety of responses were reported in literature and various response combinations were proposed to characterize an SS in rodents. The aim of this review was to narrow down those core symptoms which are essential to measure the SS in rats and mice independent from the used serotonergic drug or drug combination. In order to allow comparisons across studies, across drugs, and across laboratories, it is of importance to standardize the assessment procedure of SS responses in rodent models.
By considering the most frequently reported responses in literature we identified a set of responses in rats and mice that indicate increased serotonergic activity following 5-HT-enhancing drugs or direct 5-HT agonists. If the SS is investigated in rats we recommend that of the "traditional behavioral responses" the following six responses should be assessed: forepaw treading, head weaves, hind limb abduction, low body posture, Straub tail and tremor, whereas backward walking can be neglected. Supportive signs for an SS in rats are hyperactivity and wet dog shakes. A change in body temperature, either up-or down-regulation, is one sign of the autonomic responses which is worth to be additionally evaluated in rats. A similar set of responses should be investigated in mice. With exception of forepaw treading the SS in mice is best characterized by the "traditional behavioral responses" with focus on head weaving and hind limb abduction. In contrast to rats, backward walking should be assessed in mice, also the occurrence of Straub tail, tremor, low body posture, and hyperactivity. Of the autonomic responses only a decrease in body temperature speaks out for an SS in mice. With regard to the abundance of literature on head twitches, which in mice is induced by 5-HT 2A receptor activation, this response should still be regarded as a reliable component of the murine SS. In both species the calculation of an "overall SS" score is also reasonable if the requirement is fulfilled that all investigators use the same, i.e. above mentioned, set of responses for their studies. In order to establish an animal model of the SS in rodents combinations of 5-HT-enhancing drugs, e.g. of 5-HTP and MAOIs or tryptophan and MAOIs, can be used as positive control. Additionally, 5-HTP administered alone is useful to induce an SS in rats or mice.
One caveat that must be noted is the face validity of the animal model. Many of the SS responses observed in rats and mice are not direct correlates of the SS symptoms observed in humans. However, the triad of symptoms including neuromuscular excitation, autonomic dysregulation and mental state alteration that appear in humans corresponds to the responses measured in rodents following treatment with serotonergic drugs [22] . Neuromuscular excitations such as tremor, hypertonicity and rigidity have been observed in both humans [4, 201] and rodents [21, 74, 127, 202, 203] . Considering the different anatomy and behavioral repertoire of species it appears plausible that neuromuscular responses manifest differently in rodents and humans. Myclonus, which is a clinical symptom of the SS, might be reflected in rodents as head twitches and forepaw treading. The Straub tail response that was first described as "a condition of catatonic rigidity in mice" [204] can refer to the muscular rigidity seen in humans. Of the autonomic dysregulations, changes in body temperature appear in both rodents and humans, although species differences in the serotonergic regulation of body temperature have to be taken into account (see Section 5.2.3). The third cluster of symptoms in humans, mental status alterations, is most difficult to detect in animals. Although, hyperactivity and with some caution hyperreactivity observed in rodents have been related to agitation observed in man [22] . It has to be noted that the Hunter 5-HT toxicity criteria do not evaluate mental state alterations as a decision rule for diagnosing the SS in humans [31] . Therefore face validity of the animal model for an SS within its limitations is given to certain extent.
Bearing these aspects in mind, our analysis included the study results of various serotonergic drugs with different mechanisms of actions, i.e. direct as well as indirect agonists at 5-HT receptors. As shown, 5-HT-enhancing drugs as well as direct receptor agonists consistently induce a specific set of responses in rodents and this set of responses can be regarded as to be a validated animal model. The construct validity is given by the drugs being used, which are the same as known to induce the SS in humans. However, it seems that 5-HT receptors are differently involved in the mediation of SS responses in rodents compared to humans [5] . For example, whereas in rodents the spectrum of symptoms recorded after treatment of 5-HT 1A receptor agonists is very similar to the one after treatment of indirect 5-HT agonists, there is only little evidence for a 5-HT 1A receptor involvement in the clinical SS. Reasons for the lack of case reports after treatment with 5-HT 1A agonists might be that 5-HT 1A receptor agonists are prescribed in a lower rate than 5-HT-enhancing drugs and that an overdose is rarely ingested. However, some case reports indicate that the addition of 5-HT 1A receptor agonists to 5-HT enhancing drugs can increase the risk for the SS [61, 63] . Moreover, animal experiments suggest that exceeded 5-HT 1A receptor activation in man harbors a risk to develop the SS.
Most important for the application of an animal model in drug research is the predictive validity. The predictive validity of the animal model of the SS is proved by the use of different drugs, that stimulate the serotonergic system and that are known to induce an SS in humans. By comparing the pharmacological profiles of several 5-HT-enhancing drugs and 5-HT agonists, we revealed that the predictive validity of the animal model can be increased if at least the above mentioned core symptoms are investigated in rats and mice, and not a narrowed set of signs or even only a single SS response. The term SS has to be used with caution. A syndrome as an association of signs has to contain the essential signs. In our review we have specified the minimum number of signs in rodents which occur independently of the used drug. By using these sets of responses, a SS in rodents could be diagnosed with more certainty. This approach might bridge the gap between the animal model and the human syndrome.
Future directions for the research on the animal model of the SS
Some important future directions for animal studies of the SS include examinations of sex and strain differences, in addition to modeling possible human genetic vulnerability using transgenic rodents.
As mentioned above, few studies have directly compared SS responses in male versus female rodents. Differences in physiology and pathophysiology in men and women are well established, and sex differences in reactions to various drugs and various doses of drugs have been reported for many years. For example, MDMA has been shown to induce different and increased SS responses in women compared to men [205] . In addition, it might be of interest to investigate possible differential responses across a range of ages. In humans, age-related changes can affect drug metabolism and bioavailability, and are associated with increased adverse drug effects [206] [207] [208] .
As noted briefly above, several studies have investigated SS responses in transgenic animals, including 5-HTT (SERT) knockout mice [128, 143, 149] , 5-HT 2B receptor knockout mice [125] , mice overexpressing the 5-HT 1A receptor in distinct serotonergic projection areas in the brain [139] , and most recently in mice lacking MAOA/B [150] . Transgenic studies in mice lacking the 5-HT 2B receptor and mice with an overexpression of the 5-HT 1A receptor have helped to determine the role of these 5-HT receptors subtypes in the expression of SS responses [125, 139] . Investigations in 5-HTT and MAOA/B knockout mice have shown that mice lacking these genes show exaggerated responses following administration of 5-HTP, tramadol, and pethidine (meperidine), for example [128, 143, 149, 150] . These studies suggest that genetically modified animals might be suitable for the evaluation of the genetic vulnerability of humans with corresponding genetic polymorphisms to develop the SS. This may have implications for pharmacogenomics and personalized medicine [149, 150, 209, 210] . For example, a clinical pharmacological study noted the influence of polymorphisms in the genes for 5-HTT, COMT, and CYP2D6 on the effects of MDMA [205] . Examinations of the effects of various serotonergic compounds in additional 5-HT knockout and other transgenic mouse models will also be of importance for elucidating and understanding the underlying neurobiological mechanisms of the SS.
Utility of the animal model of the SS in preclinical and translational research
In humans, the SS has become an increasing clinical problem due to the introduction of novel serotonergic drugs, and the rising numbers of prescriptions for serotonergic drugs [5, 66, 67] . Moreover, increased awareness of the SS has been driven by the publication of case reports, and by official national and international prescription drug warnings [17, 51, 53, 67] . In view of this, the incorporation of animal models of the SS into the preclinical evaluation phase of a drug's side-effect and toxicity profile is helpful, and will be essential for risk assessment in the future. It will also be of importance to evaluate not only the side-effects of 5-HT-enhancing drugs taken at high doses, but also to evaluate the effects of these drugs at therapeutic doses taken in combination with other serotonergic compounds.
Toxic responses and side-effects such as the SS can only be experimentally evaluated in humans with caution (see below), and evidence for toxic effects is generally based on case studies of the SS, which are inconsistently reported [1] . However, animal studies do allow experimental examinations of SS responses following administration of direct and indirect 5-HT agonists, and can serve as a method to assess drugs suspected in cases of the SS in humans. For example, several case studies have reported the development of the SS in humans following ingestion of atypical opioids such as tramadol [211, 212] and pethidine (meperidine) [11, 213] . In animal studies, these drugs have been shown to induce SS behaviors in mice, including a significant "overall SS", compared to saline and morphine [149, 150] , an opioid that has not been implicated in the SS [39, 149] . More and more atypical antipsychotics possess 5-HT 1A agonist properties. As an example several case studies have shown that tandospirone alone and in combination with other 5-HT agonists triggers the SS with the first death case [63, 214, 215] . As such, the induction of the SS responses by these drugs in laboratory animals provides evidence of the accuracy and relevance of animal models in experimental analyses of drugs implicated in the SS in humans. This is of importance for making and surveying predictions of other drugs recently thought to be causative in human the SS, such as triptans [51, 53] , linezolid [54, 57] , methylene blue [54, 55] , and the 5-HT precursor 5-HTP [2] , which is available overthe-counter and suggested as a dietary supplement for depression [216] .
It is worth noting, that a controlled clinical study in healthy subjects was recently performed using the Hunter 5-HT toxicity criteria [62] . This clinical study was designed to evaluate the risk of the SS associated with the combination of a 5-HT 1A receptor antagonist with an SSRI in healthy subjects, before introducing this drug combination into clinical practice [62] . Indeed, after multipledose administration, a mild case of the SS was detected. This study exemplifies the recent increased awareness of the possible risk of the SS associated with ingestion of novel drugs and drug combinations. Before performing such studies in humans, animal models of the SS can provide an important and easy way to pre-screen new serotonergic drugs, drugs with presumed or suspected serotonergic actions, and combinations of drugs during the pre-clinical phase.
Summary and conclusion
In the current analyses, we summarized the behavioral and autonomic SS responses in rats and mice that were induced by 5-HT-enhancing drugs and 5-HT receptor agonists, administered alone or in combination. The findings suggest that these responses are consistently observed across following administration of various serotonergic drugs and drug combinations, across various strains of mice and rats, and across laboratories. In order to allow comparison between animal studies of the SS, it is of importance to standardize the assessment of responses in order to improve the utility of such animal studies. Future studies should make use of more standardized methods of assessment, should address sex and age contributions to drug response, and should include possible genetic vulnerability to drug side-effects such as the SS. The current findings can contribute to improving animal models of the SS. The need for further research into the SS is suggested by the growing importance of the SS as a medical problem.
